Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Brk Double Nickase Plasmid (h): sc-401127-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Brk Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Brk Double Nickase Plasmid (h) and Brk Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PTK6. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Brk Antibody (G-6): sc-166171
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Brk Double Nickase Plasmid (h) | sc-401127-NIC | 20 µg | $410.00 | |||
Brk Double Nickase Plasmid (h2) | sc-401127-NIC-2 | 20 µg | $410.00 |
PTK6 encodes the non-receptor tyrosine kinase Brk, a Src-related signaling enzyme that modulates phosphorylation-dependent control of proliferation, differentiation, and epithelial cell survival. Brk integrates cues from receptor tyrosine kinases and intracellular adaptors to influence pathways such as EGFR/HER family signaling, PI3K–AKT, and MAPK/ERK, with downstream effects on cytoskeletal dynamics and cell motility. In human tissues, PTK6 expression and activity are frequently studied in epithelial biology and oncogenic signaling contexts, where altered Brk-dependent phosphorylation networks have been associated with changes in growth factor responsiveness and invasive phenotypes. These features make PTK6 a useful target for dissecting kinase-driven signaling circuits and phosphoproteomic pathway rewiring in disease-relevant models.
Brk Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PTK6 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PTK6. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PTK6 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PTK6-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.